BOTULÄ°NUM TOKSÄ°NÄ°

55- Gehanno P, Deschamps E, Garay E, Bachre M, Garay RP. Vasomotor
rhinitis: clinical efficacy of azelastine nasal spray in comparison with placebo.
ORL J Otorhinolaryngol Relat Spec 2001;63:76- 81.
56- Prasanna A, Murthy PS. Vasomotor rhinitis and sphenopalatine ganglion
block. J Pain Symptom Manage 1997;13:332-38.
57- King C, Mabry RL, Mabry CS. Günhan Ö, Günhan K, Türkçe çeviri ed. Kulak
Burun Boğaz Uygulamasında Alerji. Nobel Tıp Kitapevleri.İstanbul.1998; 79-
128.
58- Choi IS, Koh YI, Koh JS, Lee MG. Sensitivity of the skin prick test and
spesificity of the serum- spesific Ig E test for airway responsiveness to house
dust mites in asthma. J Asthma 2005;42(3):197-02.
59- Schwindt CD, Hutcheson PS, Leu SY, Dykewicz MS. Role of intradermal skin
tests in the evaluation of clinically relevant respiratory allergy assessed using
patient history and nasal challanges. Ann Allergy Asthma Immmunol 2005;
94(6):627-33.
60- Borts MR, Druce HM. The use of intranasal anticholinergic agents in the
treatment of nonallergic perennial rhinitis. J Allergy Clin Immunol1992;90:
1065-70.
61- Wood CC, Fireman P, Grosman J, Wecker M, et al. Product characteristics
and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin
Immunol 1995;95:1111-16.
62- Deckers W. The chemistry of new derivatives of tropane alkaloids and the
pharmacakinetics of a new quaternary compound. Postgrad Med J 1975;
51(7):76-81.
63- Rominger KL. Chemistry and pharmacokinetics of ipratropium bromide.
Scand J Respir Dis 1979;103:116-26.
64- Borum P, Mygind N, Larsen FS. Ipratropium nasal spray: a new treatment for
perennial rhinitis. Clin Otolaryngol 1979;4:407-11.
65- Mygind N, Borum P. Effect of a cholinoceptor antagonist in the nose. Eur J
Respir Dis 1983 64(128):167-74.
66- Kim KT, Kerwin E, Landwehr L, Bernstein JA, et al. Use of 0.06% ipratropium
bromide nasal spray in children aged 2 to 5 years with rhinorrhea due to a
common cold or allergies. Ann Allergy Asthma Immunol 2005;94:73-9.
81